Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(RFZIZXWYWPNBGL-XVFCMESISA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20230026381COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF
US 26.01.2023
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
Appl.No 17930369 Applicant ModernaTX, Inc. Inventor Joshua FREDERICK

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

2.1020230008243면역 조정 폴리펩타이드를 암호화하는 mRNA의 조합물 및 이의 용도
KR 13.01.2023
Int.Class A61K 38/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
Appl.No 1020227045735 Applicant 모더나티엑스, 인크. Inventor 프레데릭, 조슈아
본 개시내용은 면역 반응 프라이머 폴리펩타이드(예를 들어, 인터류킨 23(IL-23) 폴리펩타이드 또는 인터류킨 36γ(IL-36-감마) 폴리펩타이드), 및 면역 반응 공동 자극 신호 폴리펩타이드(예를 들어, OX40L 폴리펩타이드)를 암호화하는 면역조정 폴리뉴클레오타이드(예를 들어 mRNA)의 조합물의 조성물, 이의 제조 방법 및 생산, 및 이의 치료 용도에 관한 것이다. ,
3.WO/2023/283134UTILIZATION OF ANTIBODIES TO SHAPE ANTIBODY RESPONSES TO AN ANTIGEN
WO 12.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2022/035968 Applicant REGENERON PHARMACEUTICALS, INC. Inventor MURPHY, Andrew
Described herein are methods and compositions for directing an antibody response in a subject away from one or more first epitopes of an antigen (e.g., immunodominant epitopes of a vaccine antigen) and towards one or more second epitopes of the antigen by administering one or more antibodies targeting the one or more first epitopes of the antigen.
4.20220409720VARICELLA ZOSTER VIRUS (VZV) VACCINE
US 29.12.2022
Int.Class A61K 39/25
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
25Varicella-zoster virus
Appl.No 17245973 Applicant ModernaTX, Inc. Inventor Giuseppe Ciaramella

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having a open reading reading frame encoding at least varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

5.20220387628MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS AND USES THEREOF
US 08.12.2022
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No 17618779 Applicant ModernaTX, Inc. Inventor Ruchi JAIN

The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide desirable regulation of mRNA localization, stability, and/or translation to yield increased mRNA expression and activity of an encoded polypeptide.

6.1020220159479인터류킨-12 (IL12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
KR 02.12.2022
Int.Class A61K 38/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
Appl.No 1020227040214 Applicant 모더나티엑스, 인크. Inventor 프레데릭, 조슈아
본 개시내용은 인간 인터류킨-12 (IL12), 그의 기능적 단편, 및 IL12를 포함하는 융합 단백질을 코딩하는 연결된 뉴클레오시드의 오픈 리딩 프레임을 포함하는 폴리뉴클레오티드에 관한 것이다. 일부 실시양태에서, 오픈 리딩 프레임은 서열-최적화된다. 특정한 실시양태에서, 본 개시내용은 인간 IL12의 폴리펩티드 서열을 코딩하는 뉴클레오티드를 포함하는 서열-최적화된 폴리뉴클레오티드 또는 그러한 서열 최적화된 폴리뉴클레오티드와 높은 서열 동일성을 갖는 서열을 제공한다.
7.2022177007がんの治療のためのmRNA併用療法
JP 30.11.2022
Int.Class C12N 15/24
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
19Interferons; Lymphokines; Cytokines
24Interleukins
Appl.No 2022134046 Applicant モデルナティエックス インコーポレイテッド Inventor フレデリック, ジョシュア
【課題】がんの治療のための核酸(例えば、mRNA)併用療法の使用に関する。
【解決手段】本開示は、組成物、ならびにそれらの調製、製造及び治療上の使用の方法を提供し、それらの組成物は、少なくとも2つのポリヌクレオチド(例えば、mRNA)を組み合わせて含み、少なくとも2つのポリヌクレオチドは、(i)免疫応答プライマー(例えば、IL23)をコードするポリヌクレオチド、(ii)免疫応答共刺激シグナル(例えば、OX40L)をコードするポリヌクレオチド、(iii)チェックポイント阻害剤(例えば、抗CTLA-4抗体)をコードするポリヌクレオチド及び(iv)これらの組み合わせからなる群から選択される。
【選択図】なし
8.20220370591COMPOSITIONS COMPRISING NUCLEIC ACIDS ENCODING STRUCTURAL TRIMERS AND METHODS OF USING THE SAME
US 24.11.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No 17601412 Applicant THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY Inventor Megan WISE

Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a leader sequence or a pharmaceutically acceptable salt thereof; and a second nucleic acid sequence comprising a sequence that encodes a trimer of a retroviral envelope or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker. Also disclosed are pharmaceutical compositions comprising these compositions and methods of using the disclosed compositions.

9.2022136230POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR TREATING FABRY DISEASE
JP 15.09.2022
Int.Class A61K 9/127
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
Appl.No 2022119527 Applicant MODERNATX INC Inventor PAOLO MARTINI

PROBLEM TO BE SOLVED: To provide mRNA therapy for treating Fabry disease.

SOLUTION: The mRNA for use in the present invention encodes, when administered in vivo, human α-galactosidase A (GLA), an isoform or functional fragment thereof or a fusion protein comprising the GLA. Preferably the mRNA of the invention is encapsulated in lipid nanoparticles (LNPs) to achieve, when administered to a subject, efficient delivery to the cells and/or tissues of the subject. The mRNA therapy of the invention increases and/or restores the poor GLA expression and/or activity level in the subject. The mRNA therapy of the invention further decreases the level of toxic metabolites associated with the deficient GLA activity in the subject, that is, the levels of Gb3 and lyso-Gb3.

SELECTED DRAWING: None

COPYRIGHT: (C)2022,JPO&INPIT

10.WO/2022/180213FORMULATIONS FOR AEROSOL FORMATION AND AEROSOLS FOR THE DELIVERY OF NUCLEIC ACID
WO 01.09.2022
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/EP2022/054796 Applicant ETHRIS GMBH Inventor DOHMEN,Christian
The invention relates to an aqueous suspension formulation for aerosol formation, said suspension formulation comprising lipid or lipidoid nanoparticles which are suspended in an aqueous vehicle solution, wherein the lipid or lipidoid nanoparticles comprise the following components (a) and (b): (a) a nucleic acid and (b) an ionizable lipid or an ionizable lipidoid; and wherein the aqueous vehicle solution comprises a triblock copolymer which contains one polypropylene oxide) block and two poly(ethylene oxide) blocks. Moreover, the invention relates to an aerosol obtained from the formulation for aerosol formation.